Abstract
Increasing numbers of men are being diagnosed with prostate cancer and undergo operative curative treatment. It has been suggested that outcome after radical prostatectomy (RP) may vary for different age groups.
Objective:
To investigate whether PSA recurrence-free survival after RP is related to age at operation for a cohort of English men.
Methods:
A total of 854 patients notes from four Urology units were audited for preoperative staging parameters and follow-up data obtained. The relationship of PSA, age, biopsy Gleason grade, clinical stage, era and institution on PSA recurrence-free survival was competitively assessed with a multivariate model.
Results:
Only preoperative PSA (P<0.0001) and biopsy Gleason grade (P<0.0001) were found to be strongly associated with PSA recurrence-free survival on multivariate analysis. PSA recurrence-free survival probabilities at 5 y for patients aged 45–55 y, 55.1–60 y, 60.1–65 y, 65.1–70 y and 70.1–75 y were 0.59 (CI 0.47–0.71), 0.74 (CI 0.64–0.784), 0.56 (CI 0.44–0.68), 0.61 (CI 0.53–0.69) and 0.60 (CI 0.46–0.74), respectively. No significant difference of PSA recurrence-free survival between any of the age groups was found (Log-rank, P=0.8567).
Conclusion:
No significant difference of pathological variables or biochemical recurrence across the age groups was found. The widely held belief of poorer outcome in younger men selected for RP does not seem to be borne out by this study.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 4 print issues and online access
$259.00 per year
only $64.75 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Greenlee RT et al. Cancer statistics, 2000. CA Cancer J Clin 2000; 50: 7–33.
Tjaden HB, Culp DA, Flocks RHF . Clinical adenocarcinoma of the prostate in men under 50 years of age. J Urol 1965; 93: 618–621.
Data from the National Cancer Institute's Surveillance, Epidemiology and End Results (SEER) program web site. http://seer.cancer.gov/faststats/html/inc_prost.html; 2003.
Winkler MH et al. Time trends in case selection, stage and PSA recurrence after radical prostatectomy-a multi centre audit. Br J Urol Int 2004; 93: 725–729.
Khan MA et al. Long-term cancer control of radical prostatectomy in men younger than 50 years of age: Update 2003. Urology 2003; 62: 86–91.
Riopel MA et al. Radical prostatectomy in men less than 50 years old. Urol Oncol 1995; 1: 80–83.
Alexander RB et al. Pathological stage is higher in older men with clinical B1 adenocarcinoma of the prostate. J Urol 1989; 141: 880–882.
Carter HB, Epstein JI, Partin AW . Influence of age and prostate-specific antigen on the chance of curable prostate cancer among men with non-palpable disease. Urology 1999; 53: 126–130.
Roberts WW et al. Contemporary identification of patients at high risk of early prostate cancer recurrence after radical retropubic prostatectomy. Urology 2001; 57: 1033–1037.
Winkler MH, Gillatt DA . Learning curve and stage migration of a radical retropubic prostatectomy series over a 10-y period. Prostate Cancer Prostatic Dis 2004; 7: 258–262.
Winkler MH et al. Case selection for radical prostatectomy in the UK. Eur Urol 2004; 46: 444–450.
Freedland SJ et al. Do younger men have better biochemical outcomes after radical prostatectomy? Urology 2004; 63: 518–522.
Carter HB, Epstein JI, Partin AW . Influence of age and prostate-specific antigen on the chance of curable prostate cancer among men with non-palpable disease. Urology 1999; 53: 126–130.
Oesterling JE et al. Serum prostate-specific antigen in a community-based population of healthy men: establishment of age-specific reference ranges. JAMA 1993; 270: 860–864.
Varkarakis J et al. Radical retropubic prostatectomy in men younger than 45 years diagnosed during early prostate cancer detection program. Urology 2004; 63: 337–341.
Kanto S et al. Clinical features of prostate cancer patients younger than 50 years: report of seven cases. Int J Urol 2002; 9: 91–94.
Silber I, McGabran MH . Adenocarcinoma of the prostate in men less than 56 years old: a study of 65 cases. J Urol 1971; 105: 283–285.
Johnson DE, Lanieri JP, Ayala AG . Prostate adenocarcinoma occurring in men under 50 years of age. J Surg Oncol 1972; 4: 207–216.
Johnstone PA et al. Effect of age on biochemical disease-free outcome in patients with T1–T3 prostate cancer treated with definitive radiotherapy in an equal access health care system. Int J Radiat Oncol Biol Phys 2003; 55: 964–969.
Roach M et al. Long term survival after radiotherapy alone. Radiation Therapy Oncology Group prostate cancer trials. J Urol 1999; 161: 864–868.
Alibhai SMH et al. Is there age bias in the treatment of localised prostate cancer? Cancer 2004; 100: 72–81.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Khan, F., Kaisary, A., Boustead, G. et al. PSA recurrence following radical prostatectomy is comparable for all age groups in the UK. Prostate Cancer Prostatic Dis 8, 158–162 (2005). https://doi.org/10.1038/sj.pcan.4500786
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.pcan.4500786